Survodutide (BI 456906) is a synthetic dual-agonist peptide developed by Boehringer Ingelheim targeting both GLP-1 and glucagon receptors, with a deliberately glucagon-biased activity ratio that distinguishes it from other dual agonists. While Mazdutide balances both receptor activities, Survodutide is engineered with enhanced glucagon receptor engagement specifically to maximize hepatic metabolic effects — making it the leading research tool for studying glucagon-driven liver fat reduction.
The hepatic focus of Survodutide research is grounded in glucagon receptor biology. Glucagon receptor activation on hepatocytes drives fatty acid beta-oxidation through CPT1a upregulation, stimulates ketogenesis, increases energy expenditure through futile metabolic cycling and UCP1-independent thermogenesis, and promotes amino acid catabolism via urea cycle enzyme induction. When combined with GLP-1R co-agonism providing appetite suppression, insulin secretion enhancement, and gastric emptying delay, the result is a dual-pathway approach targeting both hepatic lipid metabolism and systemic energy balance.
Published preclinical data position Survodutide as a compound of high research interest for MASH/NAFLD (metabolic dysfunction-associated steatohepatitis), where hepatic triglyceride accumulation, inflammation, and fibrosis are the primary pathological features. The glucagon-biased design directly addresses the hepatic lipid overload that is resistant to GLP-1-selective approaches alone.
Supplied as a lyophilized powder with ≥99% purity. Store at -20°C desiccated. For hepatic metabolism and endocrinology research only.
